Bextra Settlement Coming Soon: Industry Should Brace For Impact
Executive Summary
Pfizer's pending $2.3 billion settlement of an investigation into the promotion of Bextra (valdecoxib) sets a new record for a pharma company's liability in a health care fraud case, and begs the question of how big the political liability facing the industry will be as the latest wave of marketing cases reaches settlement
You may also be interested in...
Pfizer Sales Manager Gets Probation for Deleting Bextra Off-Label Data
A Pfizer sales manager was sentenced July 16 to six months of home confinement with electronic monitoring and three years of probation for obstruction of justice in the government's investigation of off-label promotion of Bextra (valdecoxib)
Pfizer Sales Manager Gets Probation for Deleting Bextra Off-Label Data
A Pfizer sales manager was sentenced July 16 to six months of home confinement with electronic monitoring and three years of probation for obstruction of justice in the government's investigation of off-label promotion of Bextra (valdecoxib)
Forest Celexa, Lexapro Off-Label Promotion, Kickbacks Alleged In DoJ Suit
Forest waged an extensive campaign to get doctors to prescribe its antidepressants Lexapro and Celexa for off-label use in children, while concealing data that Celexa was no more effective than placebo in pediatric patients, and carried an increased risk of suicide attempts, the Department of Justice claims in a 1complaint filed against the company